Ovarian Cancer Risk and Survival in BRCA 1/2 Carriers

Abstract

This project is evaluating whether oral contraceptives and parity are as protective against ovarian cancer in BRCAl/2 carriers as they are for women in general. It is also determining whether there are survival differences between BRCAl/2 carriers with ovarian cancer compared to women with sporadic disease. The study employs a case-case design. We will identify about 400 Jewish women with epithelial ovarian cancer. We will genotype these women for the 3 BRCAl/2 mutations found in Ashkenazi women. We will then compare oral contraceptive use and parity between carriers and non-carriers. We will also compare survival differences between the two groups. In the first year of the project, we have identified 36 eligible subjects. Risk factor data and pathologic specimens have been obtained on these women. Using the pathology specimens, we have genotyped the 36 subjects and identified l7 mutation carriers. To date, we are on schedule to complete this project as outlined in the original Work Plan.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2001
Accession Number
ADA406117

Entities

People

  • Francesmary Modugno

Organizations

  • University of Pittsburgh

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Cancer
  • Diseases And Disorders
  • Health Services
  • Institutional Review Board
  • Ligation
  • Lymph Nodes
  • Medical Personnel
  • Neoplasms
  • Ovarian Cancer
  • Physicians
  • Pregnancy Complications
  • Spreadsheet Software
  • Survival
  • Urogenital System

Readers

  • Gender and Food Studies
  • Molecular and genetic basis of cancer.